The ROS-induced cytotoxicity of ascorbate is attenuated by hypoxia and HIF-1alpha in the NCI60 cancer cell lines

Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial

(2013) J. L. Welsh et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Bicalutamide-induced hypoxia potentiates RUNX2-mediated Bcl-2 expression resulting in apoptosis resistance

(2012) G Browne et al.   BRITISH JOURNAL OF CANCER

Hyperbaric oxygen therapy and cancer—a review

(2012) Ingrid Moen et al.   Targeted Oncology

HIF-1α effects on angiogenic potential in human small cell lung carcinoma

(2011) Jun Wan et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Targeted therapy of glucose uptake via GLUT1 kills RCC cells

(2011) Iley Ozerlat   Nature Reviews Urology

Low Ascorbate Levels Are Associated with Increased Hypoxia-Inducible Factor-1 Activity and an Aggressive Tumor Phenotype in Endometrial Cancer

(2010) C. Kuiper et al.   CANCER RESEARCH

Hypoxia, angiogenesis and cancer therapy: To breathe or not to breathe?

(2010) Paolo Michieli   CELL CYCLE

Mechanisms of Ascorbate-Induced Cytotoxicity in Pancreatic Cancer

(2010) J. Du et al.   CLINICAL CANCER RESEARCH

High levels of oxidative stress in patients with advanced lung cancer

(2010) Hidir ESME et al.   RESPIROLOGY

Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects

(2009) Julien Verrax et al.   FREE RADICAL BIOLOGY AND MEDICINE

Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?

(2009) Dunyaporn Trachootham et al.   NATURE REVIEWS DRUG DISCOVERY

Phase I clinical trial of i.v. ascorbic acid in advanced malignancy

(2008) L. J. Hoffer et al.   ANNALS OF ONCOLOGY

Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice

(2008) Q. Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA